

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Axaron Bioscience AG	02/20/2008
RECEIVING PARTY DATA	
Name:	SYGNIS Bioscience GmbH & Co. KG
Street Address:	Im Neuenheimer Feld 515
City:	Heidelberg
State/Country:	GERMANY
Postal Code:	69120
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10276645
CORRESPONDENCE DATA	
Fax Number:	(678)420-9301
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	6784209300
Email:	jtyson@needlerosenberg.com
Correspondent Name:	Jo Anne Tyson
Address Line 1:	999 Peachtree Street, Suite 1000
Address Line 4:	Atlanta, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	07089.0014U1
NAME OF SUBMITTER:	Janell T. Cleveland, #53,848
Total Attachments: 2 source=07089_0014U1_2008_02_21_Assign#page1.tif source=07089_0014U1_2008_02_21_Assign#page2.tif	

OP \$40.00 10276645

500469052

PATENT
REEL: 020539 FRAME: 0943

**ASSIGNMENT
(U.S. RIGHTS ONLY)**

WHEREAS, Axaron Bioscience AG, a corporation of Germany, whose post-office address is Carl-Bosch-Str. 38, 67056 Ludwigshafen, Germany, is owner of the entire right, title and interest in new and useful improvements in **NEURONAL SERINE-THREONINE PROTEIN KINASE** for which a United States Patent Application was filed on November 18, 2002, and assigned Application No. 10/276,645; and

WHEREAS, SYGNIS Bioscience GmbH & Co. KG, a corporation of Germany, whose post-office address is Im Neuenheimer Feld 515, 69120 Heidelberg, Germany, is desirous of acquiring the entire interest in the same;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, **Axaron Bioscience AG** hereby does sell, assign and transfer unto said **SYGNIS Bioscience GmbH & Co. KG**, the entire right, title and interest in and to said invention and application throughout the world, including, without limitation, any Letters Patent which may issue thereon, and any subsequent application claiming priority to the above-identified application, reissue, reexamination, divisional, continuation-in-part, extension or continuation thereof and all rights of priority under the International Convention arising from said application; the same for **SYGNIS Bioscience GmbH & Co. KG'S** legal representatives and assigns, as fully and entirely as the same would have been held by us had this assignment and sale not been made;

AND, Axaron Bioscience AG hereby binds itself, its legal representatives and assigns properly to execute without further consideration any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect, the sale, assignment, transfer and conveyance hereby made or intended to be made and generally do

everything possible to aid SYGNIS Bioscience GmbH & Co. KG, its legal representatives and assigns, to obtain and enforce proper protection for said invention in all countries throughout the world.

IN WITNESS WHEREOF, I have executed this Assignment this 20th day
of Feb., 2008.

Axaron Bioscience AG

Wolf Dieter Stapp

By: [Signature] (L.S.)

Title: CEO

Witness (1)

Name: DR. CARSTEN RÖDDER

Address: c/o BASF SE

CARL-BOSCH-STR. 38, 67056

LUDWIGSHAFEN,
GERMANY

Witness: (2)

Name: CLAUDIA SCHÜTZE

Address: c/o BASF SE

CARL-BOSCH-STR. 38, 67056 LUDWIGSHAFEN,
GERMANY